AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Staar Surgical Co Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Staar Surgical has reported a significant insider transaction involving their newly appointed Chief Financial Officer, Deborah J. Andrews. On June 25, 2025, Andrews received a grant of 41,867 Restricted Stock Units (RSUs) as part of her appointment compensation package.

Key details of the RSU grant:

  • Each RSU represents the right to receive one share of common stock upon vesting
  • The RSUs will vest in three equal annual installments on June 25 of 2026, 2027, and 2028
  • The conversion price is $0, typical for RSU grants
  • The shares are held directly by Andrews

This Form 4 filing indicates a standard executive compensation arrangement, designed to align the new CFO's interests with long-term shareholder value through a three-year vesting schedule. The transaction was reported within the required two-business-day window for insider transaction disclosure.

Staar Surgical ha comunicato una significativa operazione interna riguardante la loro neo-nominata Chief Financial Officer, Deborah J. Andrews. Il 25 giugno 2025, Andrews ha ricevuto una concessione di 41.867 Restricted Stock Units (RSU) come parte del suo pacchetto retributivo di nomina.

Dettagli principali della concessione RSU:

  • Ogni RSU rappresenta il diritto a ricevere una azione ordinaria al momento del vesting
  • Le RSU matureranno in tre rate annuali uguali il 25 giugno 2026, 2027 e 2028
  • Il prezzo di conversione è di 0$, tipico per le concessioni RSU
  • Le azioni sono detenute direttamente da Andrews

Questa dichiarazione Form 4 indica un consueto accordo di compensazione esecutiva, volto ad allineare gli interessi della nuova CFO con il valore azionario a lungo termine attraverso un piano di maturazione triennale. L’operazione è stata comunicata entro la finestra obbligatoria di due giorni lavorativi per la divulgazione delle transazioni interne.

Staar Surgical ha informado una transacción interna significativa relacionada con su recién nombrada Directora Financiera, Deborah J. Andrews. El 25 de junio de 2025, Andrews recibió una concesión de 41,867 Unidades de Acciones Restringidas (RSU) como parte de su paquete de compensación por nombramiento.

Detalles clave de la concesión de RSU:

  • Cada RSU representa el derecho a recibir una acción común al momento de la consolidación
  • Las RSU se consolidarán en tres cuotas anuales iguales el 25 de junio de 2026, 2027 y 2028
  • El precio de conversión es de $0, típico en concesiones de RSU
  • Las acciones están en posesión directa de Andrews

Esta presentación del Formulario 4 indica un arreglo estándar de compensación ejecutiva, diseñado para alinear los intereses de la nueva CFO con el valor a largo plazo para los accionistas mediante un calendario de consolidación de tres años. La transacción fue reportada dentro del plazo obligatorio de dos días hábiles para la divulgación de transacciones internas.

Staar Surgicalì€ ìƒˆë¡œ 임명ë� 최고재무책임ìž�(CFO) Deborah J. Andrews와 ê´€ë ¨ëœ ì¤‘ìš”í•� ë‚´ë¶€ìž� 거래ë¥� 보고했습니다. 2025ë…� 6ì›� 25ì�, AndrewsëŠ� 임명 ë³´ìƒ íŒ¨í‚¤ì§€ì� ì¼í™˜ìœ¼ë¡œ 41,867ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ë¥� 받았습니ë‹�.

RSU ë¶€ì—¬ì˜ ì£¼ìš” ë‚´ìš©:

  • ê°� RSUëŠ� 베스íŒ� ì‹� 보통ì£� 1주를 ë°›ì„ ê¶Œë¦¬ë¥� 나타냅니ë‹�
  • RSUëŠ� 2026ë…�, 2027ë…�, 2028ë…� 6ì›� 25ì¼ì— ê±¸ì³ 3ë…„ê°„ 균등하게 베스팅ë©ë‹ˆë‹¤
  • 전환 ê°€ê²©ì€ $0ë¡�, RSU ë¶€ì—� ì‹� ì¼ë°˜ì ìž…니다
  • 주ì‹ì€ Andrewsê°€ ì§ì ‘ 보유합니ë‹�

ì� Form 4 ì‹ ê³ ëŠ� 3ë…� 베스íŒ� ì¼ì •으로 새로ìš� CFOì� ì´ìµì� 장기 주주 가치와 ì¼ì¹˜ì‹œí‚¤ê¸� 위해 설계ë� 표준 ìž„ì› ë³´ìƒ ì²´ê³„ë¥� 나타냅니ë‹�. 거래ëŠ� ë‚´ë¶€ìž� 거래 공시ë¥� 위한 필수 2ì˜ì—…ì� ë‚´ì— ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�.

Staar Surgical a signalé une transaction d'initié importante impliquant leur nouvelle Directrice Financière, Deborah J. Andrews. Le 25 juin 2025, Andrews a reçu une attribution de 41 867 unités d'actions restreintes (RSU) dans le cadre de son package de rémunération à la nomination.

Détails clés de l'attribution des RSU :

  • Chaque RSU donne droit à une action ordinaire lors de la levée des restrictions
  • Les RSU seront acquises en trois versements annuels égaux les 25 juin 2026, 2027 et 2028
  • Le prix de conversion est de 0$, ce qui est courant pour les attributions de RSU
  • Les actions sont détenues directement par Andrews

Ce dépôt du formulaire 4 indique un dispositif standard de rémunération des dirigeants, conçu pour aligner les intérêts de la nouvelle CFO avec la création de valeur à long terme pour les actionnaires via un calendrier d'acquisition de trois ans. La transaction a été déclarée dans le délai obligatoire de deux jours ouvrables pour la divulgation des transactions d'initiés.

Staar Surgical hat eine bedeutende Insider-Transaktion im Zusammenhang mit ihrer neu ernannten Chief Financial Officer, Deborah J. Andrews, gemeldet. Am 25. Juni 2025 erhielt Andrews eine Zuteilung von 41.867 Restricted Stock Units (RSUs) als Teil ihres Vergütungspakets zur Ernennung.

Wichtige Details zur RSU-Zuteilung:

  • Jede RSU berechtigt zum Erhalt einer Stammaktie bei Vesting
  • Die RSUs werden in drei gleichen jährlichen Raten am 25. Juni 2026, 2027 und 2028 vesten
  • Der Umwandlungspreis beträgt 0$, typisch für RSU-Zuteilungen
  • Die Aktien werden direkt von Andrews gehalten

Diese Form-4-Meldung zeigt eine standardmäßige Vergütungsvereinbarung für Führungskräfte, die darauf abzielt, die Interessen der neuen CFO durch einen dreijährigen Vesting-Zeitraum mit dem langfristigen Aktionärswert in Einklang zu bringen. Die Transaktion wurde innerhalb des vorgeschriebenen Zeitraums von zwei Geschäftstagen für Insider-Transaktionsmeldungen gemeldet.

Positive
  • New CFO Deborah Andrews received significant equity alignment with 41,867 RSUs vesting over 3 years, demonstrating long-term commitment and alignment with shareholder interests
Negative
  • None.

Staar Surgical ha comunicato una significativa operazione interna riguardante la loro neo-nominata Chief Financial Officer, Deborah J. Andrews. Il 25 giugno 2025, Andrews ha ricevuto una concessione di 41.867 Restricted Stock Units (RSU) come parte del suo pacchetto retributivo di nomina.

Dettagli principali della concessione RSU:

  • Ogni RSU rappresenta il diritto a ricevere una azione ordinaria al momento del vesting
  • Le RSU matureranno in tre rate annuali uguali il 25 giugno 2026, 2027 e 2028
  • Il prezzo di conversione è di 0$, tipico per le concessioni RSU
  • Le azioni sono detenute direttamente da Andrews

Questa dichiarazione Form 4 indica un consueto accordo di compensazione esecutiva, volto ad allineare gli interessi della nuova CFO con il valore azionario a lungo termine attraverso un piano di maturazione triennale. L’operazione è stata comunicata entro la finestra obbligatoria di due giorni lavorativi per la divulgazione delle transazioni interne.

Staar Surgical ha informado una transacción interna significativa relacionada con su recién nombrada Directora Financiera, Deborah J. Andrews. El 25 de junio de 2025, Andrews recibió una concesión de 41,867 Unidades de Acciones Restringidas (RSU) como parte de su paquete de compensación por nombramiento.

Detalles clave de la concesión de RSU:

  • Cada RSU representa el derecho a recibir una acción común al momento de la consolidación
  • Las RSU se consolidarán en tres cuotas anuales iguales el 25 de junio de 2026, 2027 y 2028
  • El precio de conversión es de $0, típico en concesiones de RSU
  • Las acciones están en posesión directa de Andrews

Esta presentación del Formulario 4 indica un arreglo estándar de compensación ejecutiva, diseñado para alinear los intereses de la nueva CFO con el valor a largo plazo para los accionistas mediante un calendario de consolidación de tres años. La transacción fue reportada dentro del plazo obligatorio de dos días hábiles para la divulgación de transacciones internas.

Staar Surgicalì€ ìƒˆë¡œ 임명ë� 최고재무책임ìž�(CFO) Deborah J. Andrews와 ê´€ë ¨ëœ ì¤‘ìš”í•� ë‚´ë¶€ìž� 거래ë¥� 보고했습니다. 2025ë…� 6ì›� 25ì�, AndrewsëŠ� 임명 ë³´ìƒ íŒ¨í‚¤ì§€ì� ì¼í™˜ìœ¼ë¡œ 41,867ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ë¥� 받았습니ë‹�.

RSU ë¶€ì—¬ì˜ ì£¼ìš” ë‚´ìš©:

  • ê°� RSUëŠ� 베스íŒ� ì‹� 보통ì£� 1주를 ë°›ì„ ê¶Œë¦¬ë¥� 나타냅니ë‹�
  • RSUëŠ� 2026ë…�, 2027ë…�, 2028ë…� 6ì›� 25ì¼ì— ê±¸ì³ 3ë…„ê°„ 균등하게 베스팅ë©ë‹ˆë‹¤
  • 전환 ê°€ê²©ì€ $0ë¡�, RSU ë¶€ì—� ì‹� ì¼ë°˜ì ìž…니다
  • 주ì‹ì€ Andrewsê°€ ì§ì ‘ 보유합니ë‹�

ì� Form 4 ì‹ ê³ ëŠ� 3ë…� 베스íŒ� ì¼ì •으로 새로ìš� CFOì� ì´ìµì� 장기 주주 가치와 ì¼ì¹˜ì‹œí‚¤ê¸� 위해 설계ë� 표준 ìž„ì› ë³´ìƒ ì²´ê³„ë¥� 나타냅니ë‹�. 거래ëŠ� ë‚´ë¶€ìž� 거래 공시ë¥� 위한 필수 2ì˜ì—…ì� ë‚´ì— ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�.

Staar Surgical a signalé une transaction d'initié importante impliquant leur nouvelle Directrice Financière, Deborah J. Andrews. Le 25 juin 2025, Andrews a reçu une attribution de 41 867 unités d'actions restreintes (RSU) dans le cadre de son package de rémunération à la nomination.

Détails clés de l'attribution des RSU :

  • Chaque RSU donne droit à une action ordinaire lors de la levée des restrictions
  • Les RSU seront acquises en trois versements annuels égaux les 25 juin 2026, 2027 et 2028
  • Le prix de conversion est de 0$, ce qui est courant pour les attributions de RSU
  • Les actions sont détenues directement par Andrews

Ce dépôt du formulaire 4 indique un dispositif standard de rémunération des dirigeants, conçu pour aligner les intérêts de la nouvelle CFO avec la création de valeur à long terme pour les actionnaires via un calendrier d'acquisition de trois ans. La transaction a été déclarée dans le délai obligatoire de deux jours ouvrables pour la divulgation des transactions d'initiés.

Staar Surgical hat eine bedeutende Insider-Transaktion im Zusammenhang mit ihrer neu ernannten Chief Financial Officer, Deborah J. Andrews, gemeldet. Am 25. Juni 2025 erhielt Andrews eine Zuteilung von 41.867 Restricted Stock Units (RSUs) als Teil ihres Vergütungspakets zur Ernennung.

Wichtige Details zur RSU-Zuteilung:

  • Jede RSU berechtigt zum Erhalt einer Stammaktie bei Vesting
  • Die RSUs werden in drei gleichen jährlichen Raten am 25. Juni 2026, 2027 und 2028 vesten
  • Der Umwandlungspreis beträgt 0$, typisch für RSU-Zuteilungen
  • Die Aktien werden direkt von Andrews gehalten

Diese Form-4-Meldung zeigt eine standardmäßige Vergütungsvereinbarung für Führungskräfte, die darauf abzielt, die Interessen der neuen CFO durch einen dreijährigen Vesting-Zeitraum mit dem langfristigen Aktionärswert in Einklang zu bringen. Die Transaktion wurde innerhalb des vorgeschriebenen Zeitraums von zwei Geschäftstagen für Insider-Transaktionsmeldungen gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ANDREWS DEBORAH J

(Last) (First) (Middle)
25510 COMMERCENTRE DRIVE

(Street)
LAKE FOREST CA 92630

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0(1) 06/25/2025 A 41,867 (2) (2) Common Stock 41,867 $0 41,867 D
Explanation of Responses:
1. Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting.
2. Award of RSUs granted to the Reporting Person on June 25, 2025. These RSUs will vest as to 1/3 of the shares subject to the award on each of June 25, 2026, 2027 and 2028.
Remarks:
This Form 4 reflects the RSUs granted to Ms. Andrews in connection with her appointment as Chief Financial Officer on June 25, 2025.
/s/ Nathaniel Sisitsky as attorney-in-fact for Deborah Andrews 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Restricted Stock Units (RSUs) did STAA's new CFO Deborah Andrews receive?

Deborah Andrews received 41,867 Restricted Stock Units (RSUs) from STAAR Surgical Co on June 25, 2025, in connection with her appointment as Chief Financial Officer.

What is the vesting schedule for STAA CFO Deborah Andrews' RSUs granted in June 2025?

The RSUs will vest in three equal installments, with 1/3 of the shares vesting on each of June 25, 2026, 2027, and 2028.

When was Deborah Andrews appointed as CFO of STAA?

According to the Form 4 filing remarks, Deborah Andrews was appointed as Chief Financial Officer of STAAR Surgical Co on June 25, 2025.

What is the conversion price of STAA's RSUs granted to CFO Deborah Andrews?

The conversion price for the RSUs is $0, as each restricted stock unit represents the right to receive one share of STAAR Surgical's common stock upon vesting.

Where is STAA's new CFO Deborah Andrews based?

According to the Form 4 filing, Deborah Andrews' business address is 25510 Commercentre Drive, Lake Forest, CA 92630.
Staar Surg

NASDAQ:STAA

STAA Rankings

STAA Latest News

STAA Latest SEC Filings

STAA Stock Data

896.42M
49.27M
0.55%
102.22%
9.26%
Medical Instruments & Supplies
Ophthalmic Goods
United States
MONROVIA